Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Rosalind Advisors Inc.

Rosalind Advisors Inc. raised its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 27.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,128,700 shares of the biopharmaceutical company’s stock after acquiring an additional 243,700 shares during the period. Ocular Therapeutix makes up 4.8% of Rosalind Advisors Inc.’s holdings, making the stock its 7th biggest holding. Rosalind Advisors Inc.’s holdings in Ocular Therapeutix were worth $9,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in OCUL. Intech Investment Management LLC purchased a new stake in Ocular Therapeutix during the third quarter worth about $422,000. Charles Schwab Investment Management Inc. grew its stake in shares of Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after purchasing an additional 660,080 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Ocular Therapeutix by 11.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company’s stock worth $1,133,000 after acquiring an additional 13,238 shares in the last quarter. FMR LLC boosted its holdings in Ocular Therapeutix by 7,098.7% in the third quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock valued at $3,779,000 after purchasing an additional 428,335 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of Ocular Therapeutix in the 3rd quarter valued at $544,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Activity

In related news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,895 shares of company stock valued at $283,772. Company insiders own 3.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OCUL. Needham & Company LLC began coverage on Ocular Therapeutix in a research report on Tuesday, March 11th. They set a “buy” rating and a $15.00 target price on the stock. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, Royal Bank of Canada started coverage on Ocular Therapeutix in a report on Tuesday. They issued an “outperform” rating and a $17.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus target price of $16.38.

Ocular Therapeutix Stock Up 0.9 %

Shares of NASDAQ:OCUL opened at $7.51 on Friday. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -5.69 and a beta of 1.34. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.78. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock’s 50-day moving average price is $7.57 and its two-hundred day moving average price is $8.78.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.